On August 8, 2023, Insulet Corporation ($NASDAQ:PODD) reported their earnings results for the second quarter of Fiscal Year 2023, ending June 30, 2023. Compared to the same period in the prior year, total revenue for the quarter increased by 32.4%, reaching USD 396.5 million. Net income for the quarter was also higher year-over-year, with a 178.0% increase to reach USD 27.3 million.
The stock opened at $255.0 and closed at $238.3, marking a drop of 8.6% from the previous closing price of 260.8. The company released a statement outlining all aspects of their second quarter earnings, along with an overview of the company’s financial performance for the quarter.
However, operating expenses were higher than expected due to increased development costs for new product launches.
In addition, the company provided guidance on its growth prospects for the remainder of the fiscal year. The company expects to continue to experience solid growth in sales, despite the current market conditions, citing increased demand for its products in both domestic and international markets. Going forward, INSULET CORPORATION remains focused on expanding its product portfolio and investing in research and development activities in order to continue delivering value to shareholders. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Insulet Corporation. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Insulet Corporation. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Insulet Corporation. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Insulet Corporation are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
At GoodWhale we have conducted an analysis of INSULET CORPORATION‘s health score. Our Star Chart indicates that the company has an intermediate health score of 5/10, indicating a strong ability to maintain operations in times of crisis. INSULET CORPORATION is strong in terms of growth and profitability, and medium in terms of asset. However, their dividend is weak. With this in mind, we classify INSULET CORPORATION as a ‘gorilla’, a type of company which achieves strong and stable revenue and earnings growth due to its competitive advantage. We believe that investors who are looking for a stable and high growth company may be interested in INSULET CORPORATION. Those who are looking for a reliable dividend may be better suited investing in another company. More…
Risk Rating Analysis
Star Chart Analysis
Insulet Corp is a company that manufactures and sells insulin pumps. Its main competitors are Antibe Therapeutics Inc, NuGen Medical Devices Inc, and NanoVibronix Inc. All of these companies offer similar products and services. Insulet Corp has a competitive advantage because it has a more established brand name and a larger customer base.
– Antibe Therapeutics Inc ($TSX:ATE)
Antiobiotics are a class of drugs that are used to treat infections by bacteria. Antibe Therapeutics Inc is a Canadian company that is focused on the development of safer and more effective antibiotics. The company has a market cap of 29.71M as of 2022 and a Return on Equity of -28.09%.
– NuGen Medical Devices Inc ($TSXV:NGMD)
NuGen Medical Devices Inc is a publicly traded company with a market capitalization of 6.58M as of 2022. The company has a negative return on equity of -11235.95%. NuGen Medical Devices Inc is engaged in the development, manufacture and commercialization of medical devices. The company’s products include catheters, implants, and other medical devices.
NanoVibronix Inc is a medical device company that develops and commercializes proprietary therapeutic ultrasound products. The company’s products are based on its patented NanoVibronix Platform, a unique, low-intensity, surface-based ultrasound technology. NanoVibronix’s products are used in a variety of medical applications, including wound care, urology, physical therapy, cosmetic surgery, and pain management.
NanoVibronix’s market cap is $12.04 million as of 2022. The company has a return on equity of -190.59%. NanoVibronix’s products are based on its patented NanoVibronix Platform, a unique, low-intensity, surface-based ultrasound technology. NanoVibronix’s products are used in a variety of medical applications, including wound care, urology, physical therapy, cosmetic surgery, and pain management.
Insulet Corporation reported strong financial results for the second quarter of 2023, with total revenue increasing 32.4% and net income increasing 178.0% compared to the same period the previous year. Despite the positive news, investors reacted negatively, and the stock price dropped on the day of the announcement. Insulet Corporation’s performance is certainly impressive, and investors may be wise to look at the company as a potential long-term investment option. However, investors should pay close attention to the company’s future performance in order to gauge whether these results are sustainable and indicative of future growth.